New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies.
The current treatment paradigm for psoriatic arthritis follows a target-to-target approach, with therapy guided by the predominant disease domains. Improved understanding of PsA pathogenesis has facilitated the development of novel biologic therapies beyond tumor necrosis factor inhibitors (TNFi). Nevertheless, a considerable proportion of patients may exhibit inadequate responses to certain treatment options.
For patients with mild-to-moderate disease, clinicians commonly consider oral small-molecule therapies, including NSAIDs and corticosteroids, owing to their convenient oral administration and relatively lower cost. In moderate-to-severe PsA, TNF inhibitors are generally preferred over oral small molecules, while IL-17 and IL-12/23 inhibitors are typically considered subsequent treatment options.
Among patients who do not achieve an adequate response to TNFi monotherapy, IL-17 inhibitors are generally favored over IL-12/23 inhibitors, abatacept, and tofacitinib. However, IL-12/23 inhibitors may be preferred in patients with concomitant inflammatory bowel disease (IBD) or those seeking less frequent dosing than that offered by IL-17 inhibitors.
The current PsA treatment landscape includes established therapies such as adalimumab (HUMIRA; AbbVie), apremilast (OTEZLA; Amgen), secukinumab (COSENTYX; Novartis), certolizumab pegol (CIMZIA; UCB), and bimekizumab (BIMZELX; UCB), among others.
Discover top pharmaceutical companies psoriasis psoriatic arthritis treatment @ https://www.delveinsight.com/report-store/psoriatic-arthritis-market
Some of the psoriatic arthritis drugs under development include ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others.
Reflecting continued therapeutic innovation and a substantial unmet medical need, DelveInsight estimates that the psoriatic arthritis market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is projected to expand at a significant CAGR of during the forecast period through 2036, driven by the development of novel targeted therapies, advances in biologic and small-molecule treatments, increasing investment in psoriatic arthritis research, rising disease prevalence, growing adoption of personalized treatment approaches, and continued efforts to address inadequate response and treatment-resistant disease.
Aparna Thakur, project manager of forecasting at DelveInsight, said that risankizumab and bimekizumab are expected to remain among the fastest-growing biologic therapies due to their strong efficacy across multiple psoriatic arthritis domains. Deucravacitinib and icotrokinra could expand the oral treatment segment by offering targeted, convenient alternatives to injectable biologics.
Below, we highlight 6 promising emerging late-stage therapies poised to reshape the future of the psoriatic arthritis market.
Sun Pharma’s ILUMYA/ILUMETRI (tildrakizumab-asmn)
Interleukin-23 (IL-23) inhibitor
ILUMYA/ILUMETRI (tildrakizumab-asmn), developed by Sun Pharma, is an interleukin-23 (IL-23) inhibitor. It is a humanized anti-IL-23p19 monoclonal antibody that exerts its therapeutic effects by inhibiting inflammatory signaling pathways. By selectively blocking IL-23, ILUMYA, marketed as ILUMETRI in Europe, helps regulate the production and activity of downstream inflammatory cytokines, including IL-17 and TNF-α. This mechanism reduces inflammation, limits the accumulation of inflammatory cells in psoriatic lesions, inhibits plaque formation, and promotes the resolution of tissue damage.
In March 2026, the U.S. FDA accepted Sun Pharma’s supplemental Biologics License Application (sBLA) for review, seeking approval of tildrakizumab (ILUMYA) for the treatment of adults with active psoriatic arthritis. The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of October 29, 2026.
As per Thakur, tildrakizumab is expected to see limited psoriatic arthritis uptake despite its IL-23 mechanism, as it remains more established in plaque psoriasis and faces strong intra-class competition.
MoonLake Immunotherapeutics’ Sonelokimab
IL17A protein inhibitors; IL17F protein inhibitors
Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® composed of three VHH domains covalently connected by flexible glycine-serine linkers. Through two of its binding domains, sonelokimab selectively targets IL-17A and IL-17F with high affinity, thereby blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimers.
In August 2026, MoonLake reported positive topline results from the Phase III IZAR-1 trial, with sonelokimab demonstrating significant improvements across all clinical endpoints in patients with psoriatic arthritis.
Find out the list treatments for active psoriatic arthritis drug brands that have a clear market position on price @ Psoriatic Arthritis Therapeutic Market
Johnson & Johnson’s ICOTYDE (icotrokinra)
IL-23 receptor
ICOTYDE (icotrokinra) is a targeted oral peptide and the first therapy of its kind designed to selectively block the interleukin-23 (IL-23) receptor, a key mediator of inflammatory signaling. By binding the IL-23 receptor with high affinity, icotrokinra effectively inhibits IL-23 signaling in human T cells.
In March 2026, Johnson & Johnson announced that the U.S. FDA approved ICOTYDE (icotrokinra), an IL-23 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older. The approval established ICOTYDE as the first and only targeted oral peptide therapy that selectively blocks the IL-23 receptor. The drug is currently being evaluated in Phase III clinical trials.
Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that Icotrokinra has strong disruptive potential given its novel mechanism of action and convenience, with rapid uptake in earlier lines of therapy anticipated upon approval.
Affibody Medical’s Izokibep
IL-17A inhibitor
Izokibep is an Affibody® molecule developed to selectively and potently inhibit IL-17A. At approximately one-tenth the size of a monoclonal antibody, it is engineered to penetrate tissues that can be challenging to reach. Its albumin-binding domain is designed to facilitate tissue distribution while also extending its pharmacokinetic (PK) profile. Clinical data suggest that these distinctive properties may translate into meaningful and differentiated benefits for patients, including the resolution of important disease manifestations. More than 1,000 patients have received izokibep in clinical studies, with some individuals treated for over three years.
Late-stage clinical trials evaluating izokibep in hidradenitis suppurativa and psoriatic arthritis have reported clinical responses comparable to those observed with next-generation IL-17 inhibitors. The findings further suggest that selective inhibition of IL-17A with high potency may deliver similar or superior clinical outcomes compared with therapies that target multiple IL-17 subunits, while potentially avoiding the safety concerns associated with broader IL-17 inhibition.
Explore more about which drug brands for active psoriatic arthritis are the most innovative @ Psoriatic Arthritis Treatment Drugs Safety Profile
Takeda’s Zasocitinib (TAK-279)
TYK2 kinase inhibitors
Zasocitinib is an investigational, next-generation oral TYK2 inhibitor designed to provide highly selective and potent inhibition of TYK2 over 24 hours, including suppression of IL-23 and other key immune pathways involved in disease progression. It has the potential to become a leading oral treatment option for patients with psoriasis, offering the possibility of rapid and sustained skin clearance through a convenient once-daily pill. In vitro data indicate that zasocitinib demonstrates more than 1-million-fold greater selectivity for TYK2 than other JAK enzymes, potentially enabling robust TYK2 inhibition while preserving JAK1, JAK2, and JAK3 signaling.26-27 Takeda is currently assessing the safety and efficacy of zasocitinib in Phase 3 clinical trials for psoriatic arthritis. As an investigational compound, zasocitinib has not yet been approved by any regulatory authority.
Vunakizumab (Suzhou Suncadia)
IL17A protein inhibitors
Vunakizumab (SHR-1314) is an investigational humanized monoclonal antibody targeting interleukin-17A, developed by Suzhou Suncadia Biopharmaceutical (a Jiangsu Hengrui subsidiary). It's already approved in China as of August 2024 for adults with moderate-to-severe plaque psoriasis, and the company is now expanding into psoriatic arthritis and other IL-17-driven conditions such as ankylosing spondylitis.
Download the report to understand psoriatic arthritis pipeline insights @ Best Psoriatic Arthritis Medications
Source: Psoriatic Arthritis Market Report
Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including Bristol Myers Squibb, UBC, AbbVie, Johnson & Johnson, Sun Pharmaceutical Industries, Affibody Medical, Takeda Pharmaceuticals, AltruBio, Merck Sharp & Dohme, and others.
Related Reports
JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
TNF-alpha Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TNF-alpha Inhibitors companies, including AbbVie, Amgen, Johnson & Johnson, Pfizer, UCB, Eli Lilly, Novartis, Merck, Sanofi, Boehringer Ingelheim, Samsung Bioepis, Celltrion, and others.
Interleukin-17 Inhibitors Market
Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-17 inhibitors companies, including MoonLake Immunotherapeutics, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics, Eli Lilly, UCB Pharma, Novartis, AstraZeneca, Bausch Health, Kyowa Kirin, LEO Pharma, and others.
Psoriatic Arthritis Clinical Trial Analysis
Psoriatic Arthritis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc., and others.
Psoriasis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies including Takeda, Nimbus Therapeutics, Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, Can-Fite BioPharma, Alumis, SFA Therapeutics, Novartis, Sun Pharmaceutical, Dr Reddy’s, Promius Pharma, Encore Dermatology, AbbVie, AstraZeneca, Bausch Health, Kyowa Kirin, LEO Pharma, UCB, LEO Pharma, Boehringer Ingelheim, Organon Pharmaceuticals, Eli Lilly and Company, Bristol Myers Squibb, Arcutis Biotherapeutics, Mayne Pharma, Bausch Health, MC2 Therapeutics, Almirall, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
